Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination

Po Yu Chou, Shyr Yi Lin, Yi No Wu, Chia Yu Shen, Ming Thau Sheu, Hsiu O. Ho

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Cancer vaccines have recently garnered tremendous interest. However, the targeted delivery of antigens and adjuvants to dendritic cells (DCs) still remains challenging. In this study, we developed glycosylated poly(lactic-co-glycolic acid) nanoparticles (NPs) loaded with the SIINFEKL peptide (OVA) as a tumor-specific antigen and CpG oligodeoxynucleotide (CpG) as an adjuvant for an effective DC-targeted cancer vaccine. Surface modification of NPs with galactose (Gal) or mannose (Man) was carried out by a double-emulsion solvent evaporation method, and the products were respectively named OVA-CpG Gal-NPs and OVA-CpG Man-NPs. They exhibited a uniform particle size, high loading capacity, robust stability, and extended release. The OVA-CpG Gal-NPs were found to rapidly enhance antigen uptake and DC maturation. In the in vivo study, OVA-CpG Gal-NPs via intravenous (i.v.), intranasal (i.n.) and subcutaneous (s.c.) routes had rapidly accumulated in the spleen. Moreover, the non-glycosylated OVA-CpG NPs after s.c. immunization could rapidly be trafficked to distal lymph nodes and sustained higher levels. All of these formulations increased the level of cluster of differentiation 4-positive (CD4+) T cells and interferon (IFN)-γ in the spleen, then promoted the cytotoxic CD8+ tumor-infiltrating lymphocytes against E.G7-OVA lymphomas. In conclusion, galactosylated NPs provided an effective platform to enhance the DC targeting to induce cellular immunity and T-cell recruitment into tumor sites in vivo, thus showing great potential to be developed as a prophylactic vaccine for cancer immunotherapy.

Original languageEnglish
Pages (from-to)970-988
Number of pages19
JournalJournal of Controlled Release
Publication statusPublished - Nov 2022


  • cancer immunotherapy
  • CpG ODN
  • Glycosylation
  • PLGA nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination'. Together they form a unique fingerprint.

Cite this